

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Health Technology Evaluation

Equality impact assessment – Scoping

Vorasidenib for treating astrocytoma or oligodendroglioma with IDH1 or IDH2 mutations after surgery in people 12 years and over [ID6407]

The impact on equality has been assessed during this evaluation according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

A stakeholder suggested that age should be considered because gliomas impact a younger age group.

Stakeholders also raised that people may struggle to attend hospital appointments because of socioeconomic disadvantage.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

The committee will evaluate the technology within the age group included in its anticipated marketing authorisation wording.

The committee will consider whether its recommendations could have a different impact on people protected by the equality legislation than on the wider population.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the stakeholder list been made?
--

No

Approved by Associate Director (name):

Richard Diaz

Date: 19 Nov 2024